Symptomatic Chronic Heart Failure With Reduced Ejection Fraction Therapeutics
1. Verquvo patent expiration
Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9604948 | MSD | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
Nov, 2032
(6 years from now) | |
| US10736896 | MSD | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(5 years from now) | |
| US8420656 | MSD | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993476 | MSD | Substituted 5-flouro-1H-pyrazolopyridines and their use |
May, 2031
(5 years from now) | |
| US8921377 | MSD | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(5 years from now) | |
| US11439642 | MSD | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2026 |
Drugs and Companies using VERICIGUAT ingredient
NCE-1 date: 19 January, 2025
Market Authorisation Date: 19 January, 2021
Dosage: TABLET
More Information on Dosage
VERQUVO family patents
